Answers are grounded in this paper and cite their sources.
Antibodies to the glutamate receptor 1 (GluR1) and GluR2 subunits of the α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptor (AMPAR-ab) were recently described in 10 patients from a series of 109 with limbic encephalitis (LE).1 Besides the hippocampus, GluR1/2 subunits of AMPAR are also widely expressed in the cerebral cortex, basal ganglia, and cerebellum,2 suggesting that the clinical presentation could also extend beyond the clinical profile of LE. In this study, we analyzed the presence of AMPAR-ab in a consecutive series of patients whose serum or CSF was sent to our laboratory for analysis of antineuronal antibodies in the last 2 years. ### Methods. We review all patients with final diagnosis of limbic encephalitis3 or with an immunohistochemical pattern of NMDAR-ab or AMPAR-ab in the serum or CSF (figure e-1 on the Neurology ® Web site at www.neurology.org). AMPAR-ab immunoreactivity on brain sections was confirmed on HEK293 cells transfected with plasmids containing rodent GluR1/2 subunits as described (figure).1 The study was approved by the Ethical Committee of the Hospital Clinic. Figure Immunoreactivity of antibodies against AMPA receptors (A) Section of paraformaldehyde-perfused rat brain incubated with the CSF of a patient with AMPAR-ab. There is a robust reactivity with the neuropil of hippocampus. Bar = 25 μm. (B) HEK293 cells transfected with GluR1/2 AMPAR subunits show intense reactivity with the positive CSF (green) …
No takes yet. Share an insight, caveat, or question.
Graus et al. (2010) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: